Vertex Pharmaceuticals (NASDAQ:VRTX) Announces Earnings Results

Key Points

• Vertex reported mixed quarterly results: EPS was $4.76, below the $4.82 consensus estimate, while revenue reached $3.44 billion, exceeding expectations of $3.42 billion.
• Growth remained strong across the business: Third-quarter revenue rose 12% year over year, prompting the company to raise full-year 2026 revenue guidance to $13.15 billion-$13.25 billion. ALYFTREK, CASGEVY, JOURNAVX, and PALSONIFY all contributed to commercial momentum.
• Higher costs and acquisition financing are a concern: Vertex raised full-year non-GAAP operating expense guidance to about $6 billion and added $4.5 billion in term loans related to the Crinetics acquisition. Shares fell 1% following the results, while analysts maintained an overall “Moderate Buy” rating with a $579.81 average price target.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) released its earnings results on Monday. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts' consensus estimates of $4.82 by ($0.06), FiscalAI reports. The business had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%.

Here are the key takeaways from Vertex Pharmaceuticals' conference call:

• Third-quarter revenue rose 12% year over year, and Vertex raised full-year 2026 revenue guidance to $13.15 billion-$13.25 billion, reflecting continued CF performance and growing contributions from CASGEVY, JOURNAVX, and PALSONIFY.
• Commercial momentum remained strong across newer products: ALYFTREK generated $706 million in quarterly sales, CASGEVY revenue increased 30% sequentially to $99 million, JOURNAVX prescriptions surpassed 750,000, and PALSONIFY reached $10 million in September.
• Vertex is preparing for the November 30 FDA decision on povetacicept in IgA nephropathy, highlighting its expected efficacy, tolerability, and once-monthly at-home auto-injector; the company also completed enrollment in the pivotal AMPLITUDE study of inaxaplin and expects interim data in early 2027.
• The company advanced its pipeline by prioritizing VX-017, an allogeneic, off-the-shelf islet cell therapy for type 1 diabetes, with phase I/II dosing underway and a goal of entering pivotal development next year; it also reported encouraging early results for the VX-828 next-generation CF corrector.
• Vertex increased full-year non-GAAP operating expense guidance to approximately $6 billion, including Crinetics-related costs, and incurred roughly $50 million in third-quarter financing and transaction costs; the Crinetics acquisition also added $4.5 billion in term loans at approximately 4.8% interest.

Vertex Pharmaceuticals Stock Down 1.0%

Shares of Vertex Pharmaceuticals stock traded down $5.73 on Monday, hitting $553.15. The stock had a trading volume of 3,051,427 shares, compared to its average volume of 1,388,968. Vertex Pharmaceuticals has a one year low of $403.16 and a one year high of $568.67. The stock's 50-day simple moving average is $523.21 and its two-hundred day simple moving average is $479.47. The stock has a market cap of $140.39 billion, a price-to-earnings ratio of 32.20, a PEG ratio of 2.68 and a beta of 0.28.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Royal Bank Of Canada upped their price objective on Vertex Pharmaceuticals from $570.00 to $576.00 and gave the company an "outperform" rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. started coverage on shares of Vertex Pharmaceuticals in a report on Friday, September 11th. They set an "overweight" rating and a $560.00 target price on the stock. Wall Street Zen lowered Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday. Morgan Stanley initiated coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, September 1st. They set an "overweight" rating and a $665.00 target price for the company. Finally, Barclays lifted their price objective on shares of Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an "overweight" rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $579.81.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.